Mirtazapine 30 mg as a Potential New Therapy for the Treatment of Laryngeal Sensory Neuropathy.

Objective: Laryngeal sensory neuropathy (LSN) is an irritating laryngeal disorder that may cause intractable cough, globus sensation, and frequent throat clearing. The diagnosis is typically done by exclusion, even if the postulated etiologies are viral, allergic, or idiopathic. The study aims to introduce mirtazapine 30 mg as a potential new therapy.

Protocol for dorsal ovariectomy and elastase-induced abdominal aortic aneurysm in rats.

Women have increased abdominal aortic aneurysm (AAA) growth rates and a higher rupture risk, yet hormonal effects remain unclear. We present a protocol combining dorsal ovariectomy with elastase-induced AAA formation in female rats. We describe bilateral dorsal ovariectomy, a 42-day hormone depletion period, and ventral elastase infusion for AAA induction.

A comparative 48 month randomized trial of clinical performance and wear of BISGMA based and BISGMA free nanoceramic resin composites.

This study aimed to compare the 48-month clinical performance and wear of Bis-GMA-based and Bis-GMA-free nanoceramic resin composites in Class I posterior restorations. In a randomized clinical trial, 64 patients received occlusal restorations with either Zenit (Bis-GMA-based) or Neo Spectra ST (Bis-GMA-free) nanoceramic composites (n = 32). Clinical performance was evaluated using modified USPHS criteria at four timepoints (baseline, 12, 24, 48 months).

Novel Papain-Elastase Induced Murine Model for Infrarenal Abdominal Aortic Aneurysm Rupture.

Abdominal aortic aneurysm (AAA) rupture leads to high morbidity and mortality. Current rodent models struggle to reliably mimic infrarenal AAA rupture. Chemical treatments using porcine pancreatic elastase (PPE), papain (Pap), β-aminopropionitrile (BAPN), and angiotensin II (ANG II) are known to induce AAA in rodents.

An Insight into Pharmaceutical Design and Pharmacokinetic Characteristics of GLP-1 RAs.

Introdcution: Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are among the most effective treatments for type 2 diabetes mellitus (T2DM). GLP-1 RAs stimulate pancreatic receptors, improving glycemia by boosting insulin secretion while decreasing glucagon secretion. GLP-1 receptors are present in pancreatic tissue.